Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease

A technology for Alzheimer's disease and cytokines, applied in the field of cytokine levels in the intravenous immunoglobulin therapy of Alzheimer's disease, which can solve the problems that there is no known therapy for Alzheimer's disease

Inactive Publication Date: 2014-01-29
BAXTER INT INC +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] There are currently no known treatments for Alzheimer's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
  • Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
  • Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Example 1: Changes in plasma cytokines following intravenous immunoglobulin (IVIG) treatment in patients with Alzheimer's disease (AD)

[0066] Objectives: (1) To explore changes in plasma cytokine levels associated with administration of IVIG to AD patients; (2) To compare cytokine changes with placebo-controlled, randomized II of Gammagard IVIG for mild to moderate AD associated with the clinical outcomes of the Phase 1 study.

[0067] Methods: Plasma samples were drawn from all individuals in a phase II study of IVIG for mild to moderate AD. At baseline and 6 months, plasma samples were obtained by phlebotomy before infusion. The study was performed after informed consent.

[0068] Blood draws were obtained before the first and last infusion to avoid potential confounding effects of reported short-term cytokine fluxes following IVIG infusion.

[0069] Levels of selected cytokines and chemokines were analyzed using assays optimized for the Luminex platform. Approp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of the level of certain cytokines in a patient's blood as an objective measure for the purpose of assessing disease progression in patients suffering from Alzheimer's disease and for the purpose of determining therapeutic effectiveness of a treatment regimen. Methods for treating Alzheimer's disease and monitoring therapeutic effectiveness are provided.

Description

[0001] related application [0002] This application claims priority to US Provisional Patent Application No. 61 / 470,819, filed April 1, 2011, the contents of which are incorporated herein in their entirety for all purposes. Background of the invention [0003] Alzheimer's disease is the most common form of dementia, afflicting as many as 5.3 million Americans. The disease is generally believed to be induced by the accumulation of beta-amyloid plaques in the brain, causing nerve cell death with concomitant lowering of neurotransmitter levels. Impaired memory, cognition, reasoning, and judgment result, along with decreased emotional stability and behavioral problems. The disease is progressive, causing significant mental decline and eventually death. [0004] There is currently no known cure for Alzheimer's disease. Patient care is primarily focused on managing the symptoms of the disease. Patients with Alzheimer's disease can be monitored for disease progression based on d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCC07K16/06A61K2039/545G01N33/6896A61K2039/54A61K2039/505G01N2800/2821G01N2800/52A61P25/28G01N33/48G01N33/53G01N33/68
Inventor 诺曼·R·莱尔金拉里·贝克斯理查德·西弗
Owner BAXTER INT INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com